PTC Therapeutics reported $-0.62 in EPS Earnings Per Share for its fiscal quarter ending in September of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2026 -0.62 0.27 0.20 Oct/29
FY2026Q2 Jun/2026 0.92 0.32 -0.83 Jul/30
FY2026Q1 Mar/2026 -0.03 -0.43 10.04 May/07
FY2025Q4 Dec/2025 -1.67 -0.47 -0.85 Feb/19
FY2025Q3 Sep/2025 0.20 -1.02 -1.39 Nov/04




Eps Change Date
Acadia Pharmaceuticals USD 0.31 0.13 Sep/2026
Alnylam Pharmaceuticals USD 16.26 14.42 Sep/2026
Amgen USD 6.45 0.16 Sep/2026
BioCryst Pharmaceuticals USD 0.3 0.87 Jun/2026
Biogen USD 2.62 0.98 Sep/2026
BioMarin Pharmaceutical USD 0.23 0.97 Sep/2026
Cytokinetics USD -1.37 0.13 Sep/2026
Daiichi Sankyo JPY 45.5 7.78 Sep/2026
Enanta Pharmaceuticals USD -1.05 0.31 Dec/2024
Gilead Sciences USD 2.55 9.3 Sep/2026
Incyte USD -3.6 6.69 Sep/2026
Ionis Pharmaceuticals USD 0.66 1.35 Sep/2026
Ironwood Pharmaceuticals USD 0.31 0.07 Jun/2026
Karyopharm Therapeutics USD -1.02 1.2 Mar/2026
Novartis USD 2.46 0.05 Sep/2026
Pfizer USD 0.87 0.1 Sep/2026
PTC Therapeutics USD -0.62 1.54 Sep/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Roche Holding CHF 10.98 2.61 Jun/2026
Sangamo BioSciences USD -0.18 0.1 Jun/2024
Sarepta Therapeutics USD 0.13 0.51 Sep/2026
TG Therapeutics USD 0.35 0.3 Sep/2026
Ultragenyx Pharmaceutical USD -1.16 0.26 Sep/2026
Vertex Pharmaceuticals USD 4.76 0.03 Sep/2026
Xencor USD 0.5 0.79 Sep/2026